Login to Your Account

Transgene Falls on Pexa-Vec Phase II Miss in Liver Cancer

By Cormac Sheridan
Staff Writer

Wednesday, September 11, 2013
Shares in Transgene SA dropped 13 percent last week on news that the oncolytic immunotherapy Pexa-Vec (JX-594, pexastimogene devacirepvec) failed to attain the primary endpoint of overall survival in a Phase IIb trial in 80 patients with advanced liver cancer.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription